

## TIGIT-based immunotherapeutics in lung cancer

Patel, Akshay J; Middleton, Gary W

DOI:

[10.1093/immadv/ltad009](https://doi.org/10.1093/immadv/ltad009)

License:

Creative Commons: Attribution (CC BY)

*Document Version*

Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*

Patel, AJ & Middleton, GW 2023, 'TIGIT-based immunotherapeutics in lung cancer', *Immunotherapy Advances*, vol. 3, no. 1, ltad009, pp. 1-6. <https://doi.org/10.1093/immadv/ltad009>

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

# TIGIT-based immunotherapeutics in lung cancer

Akshay J. Patel<sup>1,2,\*</sup> and Gary W. Middleton<sup>1,3</sup>

<sup>1</sup>Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK

<sup>2</sup>Department of Thoracic Surgery, University Hospitals Birmingham, Birmingham, UK


<sup>3</sup>Department of Medical Oncology, University Hospitals Birmingham, Birmingham, UK

\*Correspondence: Institute of Immunology and Immunotherapy, University of Birmingham, Vincent Drive, Edgbaston, B15 2TT, Birmingham, UK. Email: [ajp.788@gmail.com](mailto:ajp.788@gmail.com)

## Summary

In this review, we explore the biology of the TIGIT checkpoint and its potential as a therapeutic target in lung cancer. We briefly review a highly selected set of clinical trials that have reported or are currently recruiting in non-small cell and small cell lung cancer, a disease transformed by the advent of PD-1/PD-L1 checkpoint blockade immunotherapy. We explore the murine data underlying TIGIT blockade and further explore the reliance of effective anti-TIGIT therapy on DNAM-1 (CD226)-positive activated effector CD8+ T cells. The synergism with anti-PD-1 therapy is also explored. Future directions in the realm of overcoming resistance to checkpoint blockade and extending the repertoire of other checkpoints are also briefly explored.

## Graphical Abstract



**Keywords:** TIGIT, lung cancer, non-small cell lung cancer, small cell lung cancer, immunotherapy

**Abbreviations:** ES-SCLC: Extensive-stage small cell lung cancer; ICD: ITIM-containing intracellular domain; Ig: Immunoglobulin; ITIM: Inhibitory motif; ITT: Ig tail-tyrosine; LAG-3: Lymphocyte-activation gene 3; NK: Natural killer; NSCLC: Non-small cell lung cancer; ORR: Objective response rate; PFS: Progression-free survival; TRAE: Treatment-related adverse events; SCLC: Small cell lung cancer; TIGIT: T cell immunoglobulin and ITIM domain;  $T_{regs}$ : T<sub>regulatory</sub>; TILs: Tumour-infiltrating lymphocytes; TIM-3: T-cell immunoglobulin and mucin-domain containing-3; TNM: Tumour/Nodal/Metastasis; TME: Tumour microenvironment; anti-TIGIT: Atezolizumab/Carboplatin/Etoposide +/- Tirogolumab.

## Introduction

The advent of checkpoint blockade immunotherapy has revolutionised the management of solid cancers since its inception. Targeting the PD1/PD-L1 checkpoint has transformed the landscape of lung cancer and melanoma in both the early and advanced disease setting [1, 2]. Tumour evolution strategies include ways in which to evade the host immune response, which is a causal link with immunotherapy resistance [3, 4]. Research into further immunotherapeutic candidates is currently thus at the forefront of cancer research; one such candidate molecule is 'T cell immunoglobulin and ITIM domain' (TIGIT). This is an inhibitory receptor expressed on

lymphocytes that interacts with its complementary target, CD155 (Polio Virus Receptors, PVR or NECL-5) on the surface of antigen-presenting cells or tumour cells to suppress T and natural killer (NK) cell anti-tumour responses [5]. CD155 acts as a ligand for DNAM-1 (CD226) and CD96, in addition to TIGIT, which possesses the highest affinity [6]. Cross-linking of DNAM-1 and CD155 results in a cytotoxic lymphocyte stimulation, murine data has shown that DNAM-1 knockout mice demonstrate poor CD8+ T and NK cellular responses with poor tumour cell elimination and accelerated tumour growth [7, 8]. TIGIT knockout results in the loss of anti-tumour T and NK cell suppression, and this has been

Received: November 30, 2022; Accepted: May 24, 2023

© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

shown in murine models, without the added burden of high-grade autoimmune sequelae [9].

### TIGIT structure, function, and expression

TIGIT is a PVR-like protein possessing an intracellular domain, an extracellular variable immunoglobulin (Ig) domain, a type I transmembrane domain, and a cytoplasmic tail with two inhibitory motifs that are conserved in both mouse and humans: an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an Ig tail-tyrosine (ITT)-like motif [5, 10]. These motifs have been shown to mediate recruitment of the phosphatase SHIP-1 following ITT-like motif phosphorylation at Tyr225 with resultant binding to cytosolic adaptors Grb2 and  $\beta$ -arrestin 2. This results in dampened phosphoinositide 3 kinase and mitogen-activated protein kinase signalling as well as inhibition of TRAF6 and NF- $\kappa$ B activation, thus providing a mechanism by which TIGIT can act cell intrinsically to dampen activating signals [11].

The Ig variable domain shares sequence homology with DNAM-1, CD96, CD155, and other PVR-like proteins [10]. Structural analysis of TIGIT bound to CD155 reveals that two TIGIT/CD155 dimers assemble into a hetero tetramer with a core TIGIT/TIGIT cis homodimer, with each TIGIT molecule binding to one CD155 molecule. This cis–trans receptor clustering mediates cell adhesion and signalling [12, 13].

Expression is seen on T cells (CD4+, CD8+, and  $T_{\text{reg}}$  cells) and NK cells, and this can be upregulated upon cellular activation [10]. In contrast to DNAM-1, TIGIT is weakly expressed by naive T cells; in cancer, it is co-expressed with PD-1 on tumour antigen-specific CD8+ T cells and CD8+ tumour-infiltrating lymphocytes (TILs) in humans. On exhausted tumour-specific CD8+ T cell subsets, TIGIT co-expresses with other inhibitory receptors, LAG3 and TIM-3 [14].

Foxp3+  $T_{\text{reg}}$  are well known to be suppressive components of the adaptive immune response, and recent data in melanoma has demonstrated that  $T_{\text{reg}}$  exhibit increased expression of TIGIT, and decreased expression of its competing costimulatory receptor DNAM-1 as compared with CD4+ T cells resulting in an increased TIGIT/DNAM-1 ratio. TIGIT+  $T_{\text{reg}}$  are highly suppressive and enriched in tumours and correlated with poor clinical outcome upon checkpoint blockade [15]. The high expression levels of coinhibitory receptors such as TIGIT on  $T_{\text{reg}}$  is associated with their potent

immunosuppressive function, as such understanding these co-inhibitory receptors on effector T cells and  $T_{\text{reg}}$  is vitally important to developing new treatment strategies for cancer and indeed other chronic diseases. TIGIT+  $T_{\text{reg}}$  represent a highly active and suppressive phenotype with TIGIT signalling driving this phenotype with suppression of anti-tumour immunity being mediated via these  $T_{\text{reg}}$  and not CD8+ T cells [16].

TIGIT acts by binding with CD155 (cellular extrinsic mechanism), by interfering with DNAM-1 co-stimulation or by delivering direct inhibitory signals to effector cells (cellular intrinsic mechanism) [5]. CD155 cross-linking with TIGIT results in a shift of the cytokine milieu whereby dendritic cells change from a pro-inflammatory IL-12 centric to a suppressive IL-10 centric phenotype [10]. This polarisation switch has also been demonstrated in CD155 expressing macrophages that change from a type I proinflammatory phenotype to a type II suppressive phenotype [17]. TIGIT+  $T_{\text{reg}}$  are more efficacious in their ability to suppress Th1 and Th17 responses than TIGIT-  $T_{\text{reg}}$  [18]. Figure 1 illustrates the interplay and mechanisms of suppression in the TIGIT/CD155/DNAM-1 axis.

### Pre-clinical murine data in solid tumours

TIGIT-deficient mice show significantly delayed tumour growth in distinct murine models [19]; however, the number of pulmonary metastatic deposits was comparable following B16 melanoma cell inoculation in TIGIT-deficient and wild-type mice [16, 20]. Conversely, Zhang's group reported that TIGIT deficiency protected mice against secondary pulmonary metastasis [19]. TIGIT expression on CD8+ TILs is often correlated with other inhibitory receptors such as PD-1, lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin, and mucin-domain containing-3 (TIM-3), and with decreased expression of DNAM-1 [5, 8, 16, 20]. B16F10 or RM-1 cell line inoculated TIGIT knockout mice further treated with anti-TIM-3 monoclonal antibodies have demonstrated further regression of lung metastasis compared to wild-type receiving the same treatment suggesting synergism between the checkpoints [16]. This has been further illustrated in the MC38 murine model, where co-blockade of TIGIT and PD-1 enhanced the effector T cell responses more than each therapy individually and led to a 100% cure rate in these mice [21]. This has been further elicited in CT26 inoculated murine models with co-PD-L1 and TIGIT blockade, which resulted in enhanced CD8+ T cell effector responses and a 75%




Figure 1. Interplay in the TIGIT/CD155/DNAM-1 axis.

decrease in mean tumour volume after 16 days of treatment, significantly higher clearance compared to individual receptor targeting alone ( $P < 0.0001$ ) [22].

### TIGIT expression in human lung cancer

Meta-analytical data [23] from 1426 cancer patients, demonstrated that high TIGIT expression is a poor prognosticator for overall survival in solid cancers (HR 1.66, 95% CI [1.26–2.20],  $P < 0.001$ ). Subgroup analyses in lung cancer patients showed the same prognostic relationship (HR 1.29, 95% CI [0.96–1.72],  $P = 0.094$ ), albeit not significant. Retrospective data from resected lung squamous cell carcinoma specimens has shown through immunohistochemistry that 85.8% of samples expressed CD155 (PVR), compared to 26.8% expressing PD-L1 [24]. High TIGIT density and high CD155/TIGIT expression correlated with advanced Tumour/Nodal/Metastasis (TNM) stage ( $P = 0.02$  and  $P = 0.04$ , respectively) and significantly worse overall survival ( $P = 0.027$  and  $P = 0.014$ , respectively). Similar findings have been shown in independent cohorts [25]. CD155/PD-L1 co-expression is a significantly independent negative prognostic factor in squamous cell carcinoma (HR 1.76, 95% CI [1.152–2.676],  $P = 0.009$ ) [24]. CD155 and TIGIT expression has been correlated with significantly shorter overall and progression-free survival (PFS) in lung adenocarcinoma [26], and CD155 additionally has demonstrated this in small-cell lung cancer (SCLC) [27]. TIGIT expression on tumour-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) is upregulated when compared with healthy controls, but moreover, the expression dynamics of TIGIT exceed that of PD-1 in that TIGIT mRNA increased more rapidly than PD-1 mRNA, and TIGIT+ CD8+ T cells upregulated PD-1 more rapidly than TIGIT- CD8+ T cells in NSCLC patients [28].  $T_{regs}$  are well-recognised suppressors of anti-tumour effector T cell responses; CD4+ CD25+ FoxP3+ TIGIT+  $T_{regs}$  were significantly elevated in the bronchoalveolar lavage fluid and peripheral blood of NSCLC patients compared to healthy control subjects [29]. The data presented intimates the role of TIGIT as a contributor to lung cancer progression and a candidate biomarker for immunotherapeutic targeting.

### Targeting TIGIT in lung cancer

The paradigm of anti-TIGIT and anti-PD-1/PD-L1 synergism exerting better tumour control and overall survival was taken forward in a large phase II trial; CITYSCAPE [30] which reported in early 2022. Patients with locally advanced or metastatic NSCLC expressing PD-L1 in at least 1% of tumour cells and without eGFR or ALK alterations were enrolled and randomised to receive Tiragolumab (anti-TIGIT monoclonal antibody) plus Atezolizumab (anti-PD-L1) ( $n = 67$ ) or Atezolizumab alone ( $n = 68$ ). The co-primary endpoints were investigator-assessed objective response rate (ORR) and PFS as per Response Evaluation Criteria in Solid Tumours version 1.1 criteria (RECIST) [31] in the intention-to-treat population. At 5.9 months of median follow-up, 21 patients (31.3%) in the combination arm versus 11 patients (16.2%) in the anti-PD-L1 arm had an objective response ( $P = 0.031$ ). Median PFS was 5.4 months (95% CI 4.2–not estimable) in the combination arm versus 3.6 months (2.7–4.4) in the anti-PD-L1 arm (stratified hazard ratio 0.57 [95% CI 0.37–0.90],  $P = 0.015$ ). Patients with a high tumour proportion score

(TPS) of PD-L1 expression ( $>50\%$ ) ( $n = 29$ ), the differences between the treatment groups were more pronounced. ORR was 69% and 24.1% in the combination and anti-PD-L1 arm alone, respectively. In contrast, patients in the combination arm with lower PD-L1 expression (1–49%) had an ORR of 16% and a median PFS of 4 months, compared with 18% and 3.6 months in the anti-PD-L1 arm, suggesting the benefit of synergism is driven by PD-L1 expression. Grade 3–4 treatment-related adverse events (TRAE) were seen at a similar frequency in both arms (22.4% vs. 25% for combination versus anti-PD-L1 alone, respectively) as well as grade 3–4 immune-related adverse events (19.4% vs. 16%) [30]. In the phase 3 Impower110 trial [32], atezolizumab showed a significant and clinically meaningful survival benefit over chemotherapy in previously untreated patients with advanced NSCLC with high PD-L1 expression. The preliminary efficacy and safety of Tiragolumab plus atezolizumab as a first-line treatment in patients with PD-L1 high (TPS  $\geq 50\%$ ) NSCLC observed in this phase 2 study is being confirmed in an ongoing phase 3 study (SKYSCRAPER-01; NCT04294810) which is expected to enroll 560 patients. The results of this trial are encouraging and further biological interrogation and application are warranted to explore the benefit in other groups. Pre-clinical data has suggested that DNAM-1 expression maximises the impact of TIGIT blockade, and this may correlate with class I expression [33]. Banta *et al.* [33] have demonstrated a requirement of DNAM-1 expression in order to elicit maximum responses to anti-PD-1 or anti-TIGIT treatment in murine cancer models. There is differential expression of DNAM-1 and CD28 on CD8+ TILs which are regulated by the PD-1/PD-L1 and TIGIT/CD155 checkpoints, respectively. Mechanistically, PD-1 inhibited phosphorylation of both DNAM-1 and CD28 via its ITIM-containing intracellular domain (ICD); with TIGIT restricting DNAM-1 co-stimulation by blocking interaction with their common ligand PVR (CD155). Thus, full restoration of DNAM-1 signalling, and optimal anti-tumour CD8+ T cell responses, requires blockade of TIGIT and PD-1, providing a biological rationale for combinatorial targeting in the clinic [33]. DNAM-1<sup>hi</sup> CD8+ T cells accumulate at the tumour site and upon interaction with cognate antigen exhibit an exhausted phenotype, expressing high levels of PD-1, LAG-3, TIM-3, and TIGIT [34]. However, DNAM-1<sup>hi</sup> CD8+ T cells exhibit a greater capacity for self-renewal and responsiveness; it is these high expressors that are most sensitive to anti-TIGIT blockade with subsequent DNAM-1 phosphorylation at tyrosine 322 [34]. Direct antibody-mediated activation of DNAM-1 on these cytotoxic T cells augments the effect of TIGIT blockade on CD8+ T cell responses in pancreatic ductal adenocarcinoma [34]. Murine data has shown CD8+ T cell loss of DNAM-1 at the tumour microenvironment (TME) occurs in a Eomes-dependent manner but importantly limits the efficacy of checkpoint blockade [35]. Dysfunctional DNAM-1-negative CD8+ T cells accumulated in these tumours, and despite expression of co-inhibitory receptors, these cells failed to respond to anti-PD-1 treatment in the absence of DNAM-1 [35]. Enhanced CD8+ T cell effector function as a result of co-PD-1 and TIGIT blockade was abrogated by subsequent DNAM-1 blockade *in vivo* [22]. CD155 ligation with DNAM-1 results in its phosphorylation at Tyrosine 319 by Src kinases enabling its ubiquitination and clearance from the cell surface, and indeed specific mutations such as Y319F prevent phosphorylation and degradation of DNAM1, and thus

enable synergism with anti-PD-1 and enhanced anti-tumour immunity in murine models (MC38 and B16) [36]. This effectively drives resistance to checkpoint blockade, and in melanoma, the efficacy of treatment is reliant on DNAM-1+ CD8+ T cells. Mutations of Tyrosine 319 maintain DNAM-1 expression with improved anti-tumour immunity [36]. PD-1 and TIGIT double-positive T cells are predictive of enhanced anti-PD-1 activity as has been shown in melanoma and merkel cell carcinoma [37], but without the presence of DNAM-1 (marking the activation state of CD8+ T cells), there is no durable response to anti-PD-1 or indeed anti-TIGIT blockade (Fig. 1).

First in-human phase I data comparing the anti-TIGIT monoclonal antibody, Vibostolimab alone or in combination with anti-PD-1 agent Pembrolizumab has been reported in solid cancers, including NSCLC. The combination therapy was well tolerated and deemed safe in NSCLC patients with early data showing objective tumour response [38]. Thirty-nine anti-PD-1/PD-L1 therapy naive patients with NSCLC received combination therapy and demonstrated an ORR of 26% with a median PFS of 5 months (95%CI 2–8) [38]. In patients with anti-PD1 refractory NSCLC, activity was negligible both with single agent or combination (ORR 6% and 3% each) [38]. Toxicities were manageable both as a single agent or in combination with Pembrolizumab [38, 39]. No dose-limiting toxicities were seen. Three phase 3 clinical trials investigating combinations of anti-TIGIT and anti-PD-L1 or anti-PD-1 in patients with NSCLC are currently underway (NCT04738487, NCT04746924, and NCT04736173). Other phase I/II studies are underway in lung cancer exploring combinations of humanised IgG1 anti-TIGIT (Domvanalimab/AB154) in combination with anti-PD1 agent Zimberelimab (EDGE-Lung, NCT05676931) and anti-adenosine agent Etrumadenant (AB928) (NCT04791839). The ARTEMIDE-01 study (NCT04995523) will be further exploring the utility of bi-specific anti-TIGIT/anti-PD-1 antibody AZD2936 in a safety and feasibility study in metastatic NSCLC.

In extensive-stage small cell lung cancer (ES-SCLC), the addition of anti-PD-L1 in two recent randomised trials; CASPIAN [40–42] And Impower 133 has shown survival benefits over chemotherapy alone, albeit modest [36–38]. In the recently reported ASCO data from KEYNOTE-604, which treated ES-SCLC with anti-PD-1 agent, pembrolizumab in combination with Etoposide versus standard of care treatment, again the OS benefit was modest with the combination arm and did not reach significance at final analysis (HR 0.80 [95% CI 0.64–0.98],  $P = 0.0164$ ; median 10.8 vs. 9.7 months) [43]. The immune axis in this disease is thought to be far less PD-1/PD-L1 centric than in NSCLC, and avenues have been forged to seek out other checkpoints to target. SKYSCRAPER-02 (NCT04256421) [44] has recently reported its preliminary results in a phase III randomised setting whereby ES-SCLC patients are treated with Atezolizumab/Carboplatin/Etoposide +/- Tirogolumab (anti-TIGIT). A total of 490 patients were randomised. In the primary and final analysis sets, no additional benefit was seen in OS or PFS with the addition of the anti-TIGIT monoclonal antibody. No additional toxicities were observed in the quad combination arm. The final overall survival analysis is awaited, but the preliminary data from this trial suggest the immune contexture may be radically different in SCLC compared to NSCLC.

PD-1 T cell expression is crucial to PD-1/PD-L1 checkpoint blockade and especially in correlation with the DNAM-1-positive activated effector T cell phenotype; low PD-1/PD-L1 expression in SCLC [45–47] is one plausible explanation for the lack of durable response seen in the trials reported above.

## DNAM-1 agonism

DNAM-1 is a critical regulator of the response to dual TIGIT/PD-1 blockade as we have discussed above. Moreover, CD155 cross-linking with DNAM-1 potentiates NK cell cytotoxicity against tumour cells in a range of cancers. It is therefore worth discussing the therapeutic implications of DNAM-1 agonism as a therapeutic strategy in cancer whether it be as a stand-alone strategy or more appropriately in synergy with TIGIT/PD-1 blockade. The Eli-Lilly clinical trial; NCT04099277 tested agonistic anti-DNAM-1 in multiple cancers with and without Pembrolizumab. This study was terminated early but opened a door into exploring this area as a therapeutic avenue. Pre-clinical data has reliably shown the benefits of DNAM-1 agonism [48] in Multiple Sclerosis and Melanoma models. Use of immunomodulatory agent Laquinimod (Quinoline-2-Carboxamide) activated NK cells via the Aryl Hydrocarbon receptor pathway with increase in DNAM-1 surface expression in murine models. This resulted in improved NK-mediated cytotoxicity against B16F10 melanoma cells and augmented immunoregulatory functions in experimental allergic encephalomyelitis by interacting with CD155+ dendritic cells (DC). The immunosuppressive effect of Laquinimod-activated NK cells was due to decreasing MHC class II antigen presentation by DC and not by increasing DC killing [48].

## Future directions

Targeting the PD-1/PD-L1 checkpoint has occupied a stable space in the treatment of advanced NSCLC and this is still changing; the combination of nivolumab and ipilimumab demonstrated overall survival benefit in the first-line setting, regardless of PD-L1 status and Tumour Mutational Burden (Checkmate-227) [49]. However, given the pre-clinical data and early-phase randomised data discussed above, several exciting new compounds [39, 50] targeting TIGIT are currently in clinical trials and in preclinical development. These agents, when combined with PD-1/PD-L1 inhibition, seem to confer higher response rates compared to PD-1/PD-L1 inhibition alone. Questions remain regarding the setting of disease (anti-PD-1/PD-L1 naive or refractory), the combination of treatment regimens and which biomarkers will help stratify disease response (PD-L1, TIGIT, DNAM-1, components of the TME). If this can be confirmed in larger trials, the treatment paradigm and regimen will evolve dramatically and the quest for new targets (LAG3, OX40, IDO), vaccine development and harnessing the TME will certainly be of vital importance in treatment-refractory and resistant patients.

## Acknowledgements

The Editor-in-Chief, Tim Elliott, and handling editor, Marianne Boes, would like to thank the following reviewers, Patrick Greve and Alsya Affandi, for their contribution to the publication of this article.

## Author contributions

A.J.P. and G.W.M. collected the data and wrote the manuscript.

## Funding

No funding to declare in support of this work.

## Ethical approval

Not applicable.

## Conflict of interest

None declared.

## Data availability

Data derived from public domain sources.

## Permission to reproduce

Not applicable.

## Clinical Trial Registration

Not applicable.

## References

- Garon EB, Hellmann MD, Rizvi NA et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 Study. *J Clin Oncol Off J Am Soc Clin Oncol* 2019; 37(28):2518–27.
- Larkin J, Chiarion-Sileni V, Gonzalez R et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *N Engl J Med* 2019; 381(16):1535–46. <https://doi.org/10.1056/NEJMoa1910836>
- Rosenthal R, Cadieux EL, Salgado R et al; TRACERx consortium. Neoantigen-directed immune escape in lung cancer evolution. *Nature* 2019; 567(7749):479–85. <https://doi.org/10.1038/s41586-019-1032-7>
- Riaz N, Havel JJ, Makarov V et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. *Cell* 2017; 171(4):934–949.e16. <https://doi.org/10.1016/j.cell.2017.09.028>
- Harjunpää H, Guillerey C. TIGIT as an emerging immune checkpoint. *Clin Exp Immunol* 2020; 200(2):108–19. <https://doi.org/10.1111/cei.13407>
- Chan CJ, Andrews DM, Smyth MJ. Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer. *Curr Opin Immunol* 2012; 24(2):246–51. <https://doi.org/10.1016/j.coi.2012.01.009>
- Iguchi-Manaka A, Kai H, Yamashita Y et al. Accelerated tumor growth in mice deficient in DNAM-1 receptor. *J Exp Med* 2008; 205(13):2959–64. <https://doi.org/10.1084/jem.20081611>
- Gilfillan S, Chan CJ, Cella M et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. *J Exp Med* 2008; 205(13):2965–73. <https://doi.org/10.1084/jem.20081752>
- Harjunpää H, Blake SJ, Ahern E et al. Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. *Oncoimmunology* 2018; 7(7):e1445949. <https://doi.org/10.1080/2162402X.2018.1445949>
- Yu X, Harden K, Gonzalez L C et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. *Nat Immunol* 2009; 10(1):48–57.
- Li M, Xia P, Du Y et al. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon- $\gamma$  production of natural killer cells via  $\beta$ -arrestin 2-mediated negative signaling. *J Biol Chem* 2014; 289(25):17647–57. <https://doi.org/10.1074/jbc.M114.572420>
- Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. *J Immunother Cancer* 2020; 8(2):e000957. <https://doi.org/10.1136/jitc-2020-000957>
- Stengel KF, Harden-Bowles K, Yu X et al. Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell–cell adhesion and signaling mechanism that requires cis-trans receptor clustering. *Proc Natl Acad Sci USA* 2012; 109(14):5399–404.
- Chauvin JM, Pagliano O, Fourcade J et al. TIGIT and PD-1 impair tumor antigen-specific CD8<sup>+</sup> T cells in melanoma patients. *J Clin Invest* 2015; 125(5):2046–58. <https://doi.org/10.1172/JCI80445>
- Fourcade J, Sun Z, Chauvin JM et al. CD226 opposes TIGIT to disrupt Tregs in melanoma. *JCI Insight* 2018; 3(14):121–157.
- Kurtulus S, Sakuishi K, Ngiow SF et al. TIGIT predominantly regulates the immune response via regulatory T cells. *J Clin Invest* 2015; 125(11):4053–62. <https://doi.org/10.1172/JCI81187>
- Chen X, Lu PH, Liu L et al. TIGIT negatively regulates inflammation by altering macrophage phenotype. *Immunobiology* 2016; 221(1):48–55. <https://doi.org/10.1016/j.imbio.2015.08.003>
- Joller N, Lozano E, Burkett PR et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. *Immunity* 2014; 40(4):569–81. <https://doi.org/10.1016/j.immuni.2014.02.012>
- Zhang Q, Bi J, Zheng X et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent antitumor immunity. *Nat Immunol* 2018; 19(7):723–32. <https://doi.org/10.1038/s41590-018-0132-0>
- Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. *Immunity* 2016; 44(5):989–1004. <https://doi.org/10.1016/j.immuni.2016.05.001>
- Dixon KO, Schorer M, Nevin J et al. Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity. *J Immunol Baltim Md 1950* 2018; 200(8):3000–7.
- Johnston RJ, Comps-Agrar L, Hackney J et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. *Cancer Cell* 2014; 26(6):923–37. <https://doi.org/10.1016/j.ccell.2014.10.018>
- Xiao K, Xiao K, Li K et al. Prognostic role of TIGIT expression in patients with solid tumors: a meta-analysis. *J Immunol Res* 2021; 2021(10.1151):5440572. <https://doi.org/10.1155/2021/5440572>
- Yang Z, Peng Y, Xu J et al. PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma. *Transl Oncol* 2022; 24(1016):101501. <https://doi.org/10.1016/j.tranon.2022.101501>
- Peng Y, Qiu B, Tan F et al. TIGIT/CD47 dual high expression predicts prognosis and is associated with immunotherapy response in lung squamous cell carcinoma. *Thorac Cancer*. 2022; 13(14):2014–23. <https://doi.org/10.1111/1759-7714.14478>
- Sun Y, Luo J, Chen Y et al. Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma). *Int Immunopharmacol* 2020; 80(8):106198. <https://doi.org/10.1016/j.intimp.2020.106198>
- Xu Y, Cui G, Jiang Z et al. Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors. *Oncol Lett*. 2019; 17(3):2960–8. <https://doi.org/10.3892/ol.2019.9910>
- Hu F, Wang W, Fang C et al. TIGIT presents earlier expression dynamic than PD-1 in activated CD8<sup>+</sup> T cells and is upregulated in non-small cell lung cancer patients. *Exp Cell Res* 2020; 396(1):112260. <https://doi.org/10.1016/j.yexcr.2020.112260>
- Lin F, Hu X, Zhang Y et al. Upregulated TIGIT<sup>+</sup> and Helios<sup>+</sup> regulatory T cell levels in bronchoalveolar lavage fluid of

- NSCLC patients. *Mol Immunol* 2022; 147(005):40–9. <https://doi.org/10.1016/j.molimm.2022.04.005>
30. Cho BC, Abreu DR, Hussein M et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. *Lancet Oncol* 2022; 23(6):781–92. [https://doi.org/10.1016/S1470-2045\(22\)00226-1](https://doi.org/10.1016/S1470-2045(22)00226-1)
  31. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur J Cancer* 2009; 45(2):228–47. <https://doi.org/10.1016/j.ejca.2008.10.026>
  32. Herbst RS, Giaccone G, de Marinis F et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. *N Engl J Med* 2020; 383(14):1328–39. <https://doi.org/10.1056/NEJMoa1917346>
  33. Banta KL, Xu X, Chitre AS et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses. *Immunity* 2022; 55(3):512–526.e9. <https://doi.org/10.1016/j.immuni.2022.02.005>
  34. Jin HS, Ko M, Choi DS et al. CD226hiCD8+ T cells are a prerequisite for anti-TIGIT immunotherapy. *Cancer Immunol Res*. 2020; 8(7):912–25. <https://doi.org/10.1158/2326-6066.CIR-19-0877>
  35. Weulersse M, Asrir A, Pichler AC et al. Eomes-dependent loss of the co-activating receptor CD226 restrains CD8+ T cell anti-tumor functions and limits the efficacy of cancer immunotherapy. *Immunity* 2020; 53(4):824–839.e10. <https://doi.org/10.1016/j.immuni.2020.09.006>
  36. Braun M, Aguilera AR, Sundarrajan A et al. CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells. *Immunity* 2020; 53(4):805–823.e15. <https://doi.org/10.1016/j.immuni.2020.09.010>
  37. Simon S, Voillet V, Vignard V et al. PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy. *J ImmunoTher Cancer* 2020; 8(2):e001631. <https://doi.org/10.1136/jitc-2020-001631>
  38. Niu J, Maurice-Dror C, Lee DH et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆. *Ann Oncol Off J Eur Soc Med Oncol* 2022; 33(2):169–80.
  39. Florou V, Garrido-Laguna I. Clinical development of anti-TIGIT antibodies for immunotherapy of cancer. *Curr Oncol Rep* 2022; 24(9):1107–12. <https://doi.org/10.1007/s11912-022-01281-5>
  40. Paz-Ares L, Dvorkin M, Chen Y et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *The Lancet* 2019; 394(10212):1929–39.
  41. Horn L, Mansfield AS, Szczesna A et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. *N Engl J Med* 2018; 379(23):2220–9. <https://doi.org/10.1056/nejmoa1809064>
  42. Huang C, Gan GN, Zhang J. IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer. *J Hematol Oncol J Hematol Oncol* 2020; 13(1):69.
  43. Rudin CM, Awad MM, Navarro A et al. KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC). *J Clin Oncol* 2020; 38(15):9001–9001. [https://doi.org/10.1200/jco.2020.38.15\\_suppl.9001](https://doi.org/10.1200/jco.2020.38.15_suppl.9001)
  44. Rudin CM, Liu SV, Lu S et al. SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC). *J Clin Oncol* 2022; 40(7):LBA8507–LBA8507. [https://doi.org/10.1200/jco.2022.40.17\\_suppl.lba8507](https://doi.org/10.1200/jco.2022.40.17_suppl.lba8507)
  45. Carvajal-Hausdorf D, Altan M, Velcheti V et al. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TIMs in human small cell lung cancer (SCLC). *J ImmunoTher Cancer* 2019; 7(1):65. <https://doi.org/10.1186/s40425-019-0540-1>
  46. Yasuda Y, Ozasa H, Kim YH. PD-L1 expression in small cell lung cancer. *J Thorac Oncol* 2018; 13(3):e40–1. <https://doi.org/10.1016/j.jtho.2017.10.013>
  47. Acheampong E, Abed A, Morici M et al. Tumour PD-L1 expression in small-cell lung cancer: a systematic review and meta-analysis. *Cells* 2020; 9(11):2393. <https://doi.org/10.3390/cells9112393>
  48. Ott M, Avendaño-Guzmán E, Ullrich E et al. Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity. *J Neuroinflammation* 2019; 16(1):49. <https://doi.org/10.1186/s12974-019-1437-0>
  49. Hellmann MD, Paz-Ares L, Bernabe Caro R et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. *N Engl J Med* 2019; 381(21):2020–31. <https://doi.org/10.1056/NEJMoa1910231>
  50. Attili I, Passaro A, de Marinis F. Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials. *Ann Oncol Off J Eur Soc Med Oncol* 2022; 33(2):119–22.